The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis-Reference-Cited by-同舟云学术

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

Published:2024-03-18 Issue:9 Volume:103 Page:3293-3301
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Wang Zerong,Jin Xuelian,Zeng Jiajia,Xiong Zilin,Chen Xinchuan

Abstract

AbstractMyelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05703-1.pdf

Reference69 articles.

1. Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 29(11):2126–2133. https://doi.org/10.1038/leu.2015.233

2. Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, DiPersio JF (2014) Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS ONE 9(10):e109799. https://doi.org/10.1371/journal.pone.0109799

3. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https://doi.org/10.1186/s13045-017-0417-z

4. Hernández-Boluda JC, Czerw T (2022) Transplantation algorithm for myelofibrosis in 2022 and beyond. Best Pract Res Clin Haematol 35(2):101369. https://doi.org/10.1016/j.beha.2022.101369

5. Ibrahim U, Petrone GEM, Mascarenhas J, Keyzner A (2020) Peritransplantation Use of Ruxolitinib in Myelofibrosis. Biol Blood Marrow Transpl 26(12):2177–2180. https://doi.org/10.1016/j.bbmt.2020.08.015